MARKET

DARE

DARE

Dare Bioscience
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.940
+0.050
+2.65%
Pre Market: 1.940 0 0.00% 08:37 03/08 EST
OPEN
1.938
PREV CLOSE
1.890
HIGH
1.955
LOW
1.600
VOLUME
2.32K
TURNOVER
--
52 WEEK HIGH
3.850
52 WEEK LOW
0.7500
MARKET CAP
80.70M
P/E (TTM)
-2.1558
1D
5D
1M
3M
1Y
5Y
These 2 Penny Stocks Are Well Positioned for Gains, Say Analysts
The stock markets have been on a roller-coaster ride in recent sessions. However, while volatility is ruling for now, some market watchers see a rising trend on the ne...
TipRanks.com · 3d ago
Daré Bioscience to Present at the H.C. Wainwright Global Life Sciences Conference
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the H.C. Wainwright Global ...
GlobeNewswire · 6d ago
Dare Bioscience to Participate in Maxim Group's Late Stage Innovations in Women's Health Virtual Event
GlobeNewswire · 02/25 13:00
8-K: Dare Bioscience, Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/16 16:31
Daré Bioscience to Participate at the Womens Health Innovation Series: Contraception Innovation Summit to be held Virtually on February 23, 2021
SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a live panel discussion ...
GlobeNewswire · 02/16 13:00
Dare Bioscience to Present at the 2021 BIO CEO & Investor Digital Conference
Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the BIO CEO & Investor Digital Conference that will take place virtually ...
GlobeNewswire · 02/09 13:00
8-K: Dare Bioscience, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/02 00:17
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 01/21 13:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DARE. Analyze the recent business situations of Dare Bioscience through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DARE stock price target is 5.20 with a high estimate of 9.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 31
Institutional Holdings: 4.98M
% Owned: 11.96%
Shares Outstanding: 41.60M
TypeInstitutionsShares
Increased
8
2.30M
New
8
467.92K
Decreased
1
7.45K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Secretary/Director
Sabrina Johnson
Chief Financial Officer
Gregg Beloff
Chief Financial Officer
Lisa Walters-Hoffert
Chief Accounting Officer/Controller/Treasurer
Jame O'Neill
Other
John Fair
Independent Director
Cheryl Blanchard
Independent Director
Jessica Grossman
Independent Director
Steve Hall
Independent Director
Susan Kelley
Independent Director
Gregory Matz
Independent Director
Robin Steele
No Data
About DARE
Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Webull offers kinds of Dare Bioscience Inc stock information, including NASDAQ:DARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DARE stock methods without spending real money on the virtual paper trading platform.